<DOC>
	<DOCNO>NCT00028106</DOCNO>
	<brief_summary>This study evaluate effectiveness 131MIBG treat malignant pheochromocytoma whether sensitization medication improve response treatment . Pheochromocytoma rare type tumor usually occur adrenal gland . The tumor cell release chemical like adrenaline cause large increase blood pressure pulse rate , serious health consequence . Tumor adrenal gland usually remove surgically , pheochromocytoma malignant-i.e. , spread many site body-or located place surgery difficult impossible , satisfactory treatment available . 131MIBG combination adrenaline-like chemical radioactive form iodine . The 131MIBG attache tumor cell high concentration radioactive iodine kill . Previous study use 131MIBG treat pheochromocytoma 36 % response rate term complete partial improvement . This study examine whether add sensitization medication 131MIBG treatment regimen enhance effectiveness reduce size number tumor . Patients 18 year age old malignant inoperable pheochromocytoma may eligible 18-month study . Candidates screen various test procedure , may include medical history , physical examination , blood urine test , lung function study , electrocardiogram , echocardiogram , compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , positron emission tomography ( PET ) , bone scan scan use radioactive MIBG octreotide . Participants randomly assign one two treatment group : 1 ) 131MIBG plus sensitization medication , 2 ) 131MIBG alone . All patient hospitalize 3 5 day 131MIBG treatment . The drug infuse vein ( intravenously , I.V . ) 10 30 minute . Patients receive 3 treatment , separate least 3 month . All patient also take potassium protect thyroid gland radioactive iodine generate 131MIBG . The potassium take twice day 30 day , begin day 131MIBG treatment . Patients sensitization group receive follow additional drug sensitization : methylprednisolone , intravenously minute 131MIBG treatment ; Roaccutan , mouth ( capsule ) twice day 6 week treatment ; Demser , mouth 3 time week 1 week treatment , Carbidopa , mouth every 6 hour 4 day treatment . After treatment , patient clinical evaluation periodic blood test check adverse side effect radiotherapy . Follow-up visit NIH schedule 12 18 month first 131MIBG treatment clinical , laboratory imaging test . Patients tumor lung treatment lung function test 1 , 3 , 6 month treatment . CT , MRI 131MIBG , PET scan do 1 week treatment . Patients tumor grow 25 % none shrink 50 % develop one new tumor 131MIBG treatment take study .</brief_summary>
	<brief_title>131MIBG Treat Malignant Pheochromocytoma</brief_title>
	<detailed_description>Pheochromocytomas tumor chromaffin cell synthesize catecholamine . This project test efficacy radiotoxic treatment malignant pheochromocytoma use ( 131 ) I-metaiodobenzylguanidine [ ( 131 ) I-MIBG ] , particular , test whether pre-treatment enhancer pharmaceutical increase efficacy experimental ( 131 ) I-MIBG treatment reduce size number tumor tumor burden .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients malignant pheochromocytoma define locallyinvasive adrenal tumor and/or metastatic extraadrenal tumor locate tissue chromaffin cell normally present . Histologic proof pheochromocytoma require nature tumor confirm either surgical pathological diagnosis biochemical measurement . Patients may single multiple tumor . There must least one discrete metastatic tumor detect measured CT MRI . Metastatic tumor site may may resectable . The tumor ( ) must concentrate [ 131 ] IMIBG . Tumors may stable , grow increase number time study . There limit tumor size . Patients adult , male female , limit ethnic racial group . Patients Karnofsky score least 60 % . Women childbearing potential must practice effective method birth control participate study . All men must also practice effective method birth control study . EXCLUSION CRITERIA : Pregnant lactate woman exclude . A positive pregnancy test exclude patient participation protocol . Children ( less 18 year age ) patient older 70 year age exclude . Patients exclude : Impaired cardiovascular function ( ejection fraction le 40 % , symptomatic congestive heart failure , sustain blood pressure 190/100 , angina pectoris ) ; Abnormal coagulation parameter ( PT PTT elevate 30 % normal ) ; Hematocrit 30 % , hemoglobin 10 g/dl , white blood cell count 3000 per mm ( 3 ) , absolute neutrophil count 1000 per mm ( 3 ) , platelet count 100,000 per mm ( 3 ) ) ; Any reason accept blood transfusion may need treatment myelotoxicity experimental [ 131I ] MIBG therapy ; Liver enzymes great 2.5 time upper limit normal ; serum bilirubin great 1.5 time upper limit normal . Renal dysfunction ( serum creatinine great 2.0 mg/dl ) ; Life expectancy le 3 month ; Weight 136 kg , This limit scan table ; Combined blood withdrawal great 450 ml six week precede study ; Impaired mental capacity precludes write informed consent . Prior experimental treatment [ 131I ] MIBG , [ 90Y ] octreotide ( alternative agent investigate treat pheochromocytoma ) , chemotherapy exclude patient , treatment receive previous 3 month provide patient meet entry criterion . Labetalol , reserpine , calcium channel blocker , tricyclic antidepressant , phenylephrine , phenylpropanolamine , pseudoephedrine , ephedrine , atypical antidepressants/antipsychotics interfere uptake [ 131I ] MIBG pheochromocytoma . If patient change noninterfering pharmaceutical , ineligible study . Due potiential immunosuppressive effect radiation therapy , patient positive HIV exclude study . Patients hepatitis B hepatitis C exclude due potential liver toxicity . Patients receive high dose chemotherapy bone marrow transplant therapy stem cell infusion exclude . Patients receive radiation therapy pelvis and/or spine exclude . Local radiation therapy one site ( exclude pelvis/spine ) permit provide least 1 year lapse patient meet entry criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 21, 2008</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Fluorodopamine</keyword>
	<keyword>PET</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Catecholamines</keyword>
	<keyword>Metanephrines</keyword>
	<keyword>Alpha-Methyl-Para-Tyrosine</keyword>
	<keyword>Retinoic Acid</keyword>
	<keyword>Carbidopa</keyword>
</DOC>